CASI Pharmaceuticals (CASI) Getting Somewhat Favorable Press Coverage, Report Shows
Media stories about CASI Pharmaceuticals (NASDAQ:CASI) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. CASI Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 48.3955692752943 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Separately, BidaskClub downgraded shares of CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 19th.
Shares of CASI Pharmaceuticals stock opened at $6.87 on Friday. CASI Pharmaceuticals has a 52-week low of $0.95 and a 52-week high of $8.89. The company has a quick ratio of 26.01, a current ratio of 26.01 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $604.41 million, a P/E ratio of -38.17 and a beta of 0.86.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer.
Read More: Average Daily Trade Volume – ADTV
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.